• About Us
    • Company
    • Chairman’s Message
    • Team
    • Course
    • Corporate Culture
    • Honour
  • Technology
    • Research and Develop
    • Innovation Platform
    • Research and Development Pipeline
    • Innovative Drugs
  • Product
    • Digestive System
    • Cardiovascular System
    • Endocrine System
    • Nervous System
    • Inflammation
  • News
    • Company News
    • Media Coverage
  • Investor
    • Announcements and Circulars
    • Financial Reports
    • Prospectus
    • Corporate Governance
    • Contact
  • Attract Talents
    • Talent Development
    • Recruitment Position
  • Contact Us
    • Contact Us
    • Product Consultation
  • En
    • 中文
    • 繁体
    • EN
  • 中文
  • 繁体
  • EN
  • About Us
  • Company
  • Chairman’s Message
  • Team
  • Course
  • Corporate Culture
  • Honour
  • Technology
  • Research and Develop
  • Innovation Platform
  • Research and Development Pipeline
  • Innovative Drugs
  • Product
  • Digestive System
  • Cardiovascular System
  • Endocrine System
  • Nervous System
  • Inflammation
  • News
  • Company News
  • Media Coverage
  • Investor
  • Announcements and Circulars
  • Financial Reports
  • Prospectus
  • Corporate Governance
  • Contact
  • Attract Talents
  • Talent Development
  • Recruitment Position
  • Contact Us
  • Contact Us
  • Product Consultation
Investor
  1. Home
  2. Investor
  3. Announcements and Circulars
Announcements and Circulars Financial Reports Prospectus Corporate Governance Contact
  • 2025
CHANGE OF JOINT COMPANY SECRETARY, AUTHORIZED REPRESENTATIVES AND PROCESS AGENT AND WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING RULES
2025-11-21
Download
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2025
2025-11-05
Download
ANNOUNCEMENT OF FINAL OFFER PRICE AND ALLOTMENT RESULTS
2025-10-20
Download
[Other - Miscellaneous]DELAY IN LISTING TIMETABLE
2025-10-16
Download
Global Offering
2025-10-09
Download
About Us
Technology
Product
News
Investor
Attract Talents
Contact Us

Fujian Haixi New Pharmaceutical Creation Co., Ltd. Fujian ICP Record No. 12015727 Internet Drug Information Service Qualification Certificate No.: (Min) - Non-operating-2023-0063

Some of the text and pictures on this site are from the Internet and are only used for sharing and learning. If your rights and interests are infringed, please inform us in time, and this site will deal with or replace them in time.